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Summary
Monitoring the progression of osteoarthritis (OA) and the effects of therapy during clinical trials requires valid and reliable outcome
measurements. This paper discusses the selection of outcome measures in Phase III clinical trials of OA, the importance of presenting these
variables in terms of the response of individual patients, and the combination of information from several outcome measures into a composite
index. Four domains – pain, physical function, patient global assessment, and joint imaging (for studies 1 year in duration) – have been
identified as core outcome measures for Phase III clinical trials of OA. Within the symptom severity domains, several measurement
instruments may be considered, including visual analog scales (VAS), the Western Ontario McMasters Universities Osteoarthritis (WOMAC)
Index, the Lequesne Functional Severity Index, and the Arthritis Impact Measurement Scales (AIMS). Imaging techniques consist of
radiography, magnetic resonance imaging (MRI), or other techniques. Although evaluation of these variables is often based on the average
improvement in the study population as a whole, evaluation in terms of individual patients is more relevant. Therefore, continuous data
collected from individuals (e.g., pain VAS 0-100 mm) require conversion to a dichotomous variable (e.g., improvement yes/no) so that the
percentage of responders can be determined. Continuous data from individual patients’ data may be converted to a dichotomous variable
based on global assessments, statistical modeling, or predictive capacities. Such methods suggest that a change in joint space width of
≥0.5 mm may be considered clinically relevant. A composite index combining symptomatic and structural efficacy variables, adverse events,
costs, and the requirement for surgery into a single variable would be useful. The requirement for total hip arthroplasty has been evaluated
as a composite outcome measure for trials of hip OA and found to be valid, simple, and clinically pertinent.
© 2003 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Introduction
Monitoring the progression of osteoarthritis (OA) and the
effects of therapy during clinical trials requires the use of
valid and reliable outcome measurements that are simple
to perform and sufficiently sensitive to detect changes in
the patient’s condition. This paper discusses the selection
of outcome measures in Phase III clinical trials of OA, the
importance of presenting these variables in terms of the
response of individual patients, and the combination
of information from several outcome measures into a
composite index.
Selection of outcome measurements
The 1996 meeting of OMERACT (Outcome Measures in
Arthritis Clinical Trials), an initiative exploring outcome
measurement across the spectrum of rheumatology inter-
vention studies1, focused on establishing a core set of
outcome measures for future Phase III clinical trials in OA2.
During the conference, consensus was reached among at
least 90% of the participants that four core domains should
be evaluated in Phase III clinical trials of knee, hip, and
hand OA (Fig. 1). Three of these four domains – pain,
physical function, and patient global assessment – are
related to the severity of the symptoms of disease. The
fourth, considered necessary for studies of one year or
longer, consists of joint imaging (using standardized
methods for taking and rating radiographs or any superior
imaging techniques)2. A middle core of domains, believed
to be mandatory for inclusion in the core set of domains by
36% to 90% of participants, consists of health-related
quality of life measures and physician global assessment.
An outer core of domains, considered mandatory for inclu-
sion by 8% to 36% of participants, consists of measures of
stiffness, biologic markers, measurements of inflammation,
and other assessments. In this hierarchy of outcome
measures, measures that are highly relevant to the patient
are at the core of the system, while measures less relevant
to patients are at the periphery.
Within each of the three core domains related to
symptom severity, several measurement instruments may
be considered. Pain is often measured with a simple visual
analog scale (VAS) and functional impairment with the
Western Ontario McMasters Universities Osteoarthritis
(WOMAC) Index3. Global assessment may be evaluated
with a Likert scale or a VAS, which is easier to analyze from
a statistical point of view. Other possible instruments
include the Lequesne Functional Severity Index4 and the
Arthritis Impact Measurement Scales (AIMS)5. Imaging
techniques could consist of radiography, magnetic reso-
nance imaging (MRI), or other techniques. Any imaging
technique employed requires standardized methods for
both taking and scoring images2.
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Presentation of outcome measures on the basis
of individual patients
Although defining a core set of domains for evaluation
represents an important advance in standardizing the con-
duct of clinical trials in OA, analysis of these variables
continues to be based on the average improvement for the
study population as a whole. Thus, the average change in
one group of patients is compared with the average change
in a comparator group of patients. In fact, it is more
clinically relevant to express the results of analyses in
terms of individual patients. For example, the percentage of
individual patients who improve during a study is more
meaningful than the average change in pain or WOMAC
score. Response data for individual subjects are frequently
collected on the case report form by means of a continuous
variable, such as a VAS. Ultimately, it is desirable to
present the results of a study as a dichotomous response
variable, such as improvement or no improvement, so that
the percentage of patients responding to treatment can be
determined. There is a need, therefore, to convert con-
tinuous data for the individual (e.g., pain VAS 0-100 mm)
into a dichotomous variable (e.g., improvement yes/no).
Several approaches can be used to determine a
cut-off point above which changes in continuous variables
observed during a study would be considered indicative of
significant OA progression. Significant progression can be
defined on the basis of an intuitive global assessment of
disease progression given by the patients themselves or by
an expert; on the basis of distribution-based models that
describe the distribution of a measure in the population; or
on the basis of predictive models based on evidence
derived through experiment.
Ehrich et al.6 determined the minimal perceptible clinical
improvement for the WOMAC subscales using a technique
that ‘anchored’ these scores to the patient’s own global
assessment of his or her response to therapy. Patient
global assessments and the change in WOMAC scores
after treatment with placebo or anti-inflammatory agents
were evaluated using pooled data from two identical
6-week trials in 1545 patients with OA of the hip or knee6.
Minimal perceptible clinical improvement was defined as
the difference in the mean changes from baseline in
WOMAC scores (100 mm normalized VAS) between
patients with a poor global response (score of 1) and
patients with no global response (score of 0). The results of
the evaluation are presented in Table I. In this analysis,
mean changes of 9 to 11 mm on the 100-mm VAS WOMAC
subscale reflected the minimal perceptible clinical improve-
ments, although not necessarily the clinically relevant
improvement.
Expert opinion of disease progression also can be used
as the basis for determining clinically significant changes in
continuous measures of structural parameters, such as
change in joint space width (JSW). Maillefert et al.7 con-
ducted a study to determine the minimum clinically import-
ant difference (MCID) in JSW progression in patients with
hip OA. They selected a sample of 298 patients with hip OA
from a longitudinal 3-year follow-up study. Pelvic radio-
graphs were taken at entry and after 3 years. The narrow-
est JSW was measured, and the difference between the
JSW measurements at baseline and 3 years was calcu-
lated. In addition, two senior radiologists who were experts
in OA evaluated each pair of radiographs and determined,
Fig. 1. Outcome measures for osteoarthritis considered appropriate for inclusion in a core set of outcome measurements that would be
considered mandatory in future Phase III clinical trials in hip, knee, and hand OA. Measurements in the inner core were considered
mandatory by 90% of the participants at OMERACT III; measurements in the middle core were considered mandatory by 36% to 90% of
participants; and measurements in the outer core were considered mandatory by 8% to 36% of participants. (Adapted from Reference 2 with
permission from the Journal of Rheumatology.)
Table I
Minimal perceptible clinical improvement (MPCi) in the Western
Ontario McMasters Universities Osteoarthritis (WOMAC) index
and global assessments in patients with hip or knee osteoarthritis
(Ehrich et al., 1999)
Item Scale MPCi
WOMAC pain (mm) 0–100 9.7
WOMAC physical function (mm) 0–100 9.3
WOMAC stiffness (mm) 0–100 10.0
Patient global assessment of disease (mm)* 0–100 12.0
Investigator global assessment of disease (units)† 0–4 0.5
*Scale of 0=very well to 100=very poor.
†Scale of 0=very well to 4=very poor.
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on the basis of the whole joint, whether a clinically relevant
deterioration of OA stage from baseline to 3 years had
occurred. For each difference from baseline to 3 years in
JSW, the sensitivity and specificity for MCID, defined as the
assessment of the experts, were calculated. On the basis
of receiver operating characteristics (ROC) curves, the best
measured JSW threshold, with the maximal true positive
and the minimal false positive results, was calculated. The
best measured JSW threshold was −0.4 mm for Expert 1,
Expert 2, and the combination of both. These findings
suggest that a change of at least 0.4 mm in the radiological
JSW could be considered clinically relevant. Additional
study in other sets of patients using different methods of
evaluation is needed to validate these findings.
The clinical relevance of changes in JSW can also
be determined through a statistical approach. Dougados
et al.8 used statistical methods proposed by Bland and
Altman9 to determine a cut-off value for changes in JSW
that could be used to define radiological progression of hip
OA that were not related to measurement methods errors.
The statistical methods used involved calculating the mean
of the differences between two analyses to evaluate inter-
and intraobserver reliability. Data were collected during a
prospective, randomized, double-blind, placebo-controlled,
longitudinal epidemiological study in a cohort of 507
patients with primary OA of the hip (ECHODIAH Study)10.
Radiographs were taken at study entry and after 1 year,
and JSW was measured for each pair of radiographs by a
single observer. Thirty pairs of radiographs representative
of a wide range of OA severity were selected for evaluation
of intra- and interobserver reliability. Differences in
measurements between two observers were used to deter-
mine interobserver reliability, and differences between two
analyses by the same observer were used to determine
intraobserver reliability. These analyses were performed on
both the 30 films taken at study entry and the pairs of films
taken at entry and after 1 year. In addition, the intraclass
coefficient of correlations that existed between the observ-
ers (interobserver reliability) and between two analyses
(intraobserver reliability) were evaluated. The means of the
differences in change in JSW from entry to 1 year
measured in two analyses by the same observer (intra-
observer reliability) was 0.01±0.28 mm (S.D.). Radiological
progression was defined therefore by a change in JSW that
was greater than the 95% confidence interval of these
differences, a change of at least 0.56 mm. Thus, a change
in JSW of greater than 0.5 mm can be considered clinically
relevant and provides a dichotomous variable (progression
yes/no) for radiological progression. Additional indepen-
dent studies performed by other investigators will be
needed to confirm the validity of this cut-off value.
The predictive validity of an outcome measure, the extent
to which a change in measure over the short term is
predictive of a change in a ‘relevant’ (hard) end-point in the
long term, can also be used to determine a cut-off point for
clinically significant change in continuous variables.
Maillefert and colleagues determined a cut-off point for
change in JSW on the basis of the predicted need for
subsequent total hip arthroplasty (THA)11. In a 5-year
longitudinal study in patients with hip OA, change in JSW
was measured in millimeters from baseline to 2 years in
384 patients. The end-point of the study was the require-
ment for THA at 5 years. The cut-off point above which a
decrease in JSW between baseline and 2 years of
follow-up could be considered relevant was determined on
the basis of the predicted need for THA during the remain-
ing years of the study. For each observed change in JSW,
the sensitivity and specificity for subsequent THA were
calculated. The cut-off value for JSW change was chosen
on the basis of maximal sensitivity and specificity using an
ROC curve analysis. The investigators determined that
changes in JSW from baseline to 2 years of 0.4 mm or
greater were the best predictors of the requirement for THA
(Fig. 2). Fewer than 15% of the patients with a change in
JSW of less than 0.4 mm required subsequent surgery.
In contrast, roughly 60% of the patients with a change in
JSW of over 0.4 mm during the 2 years of this study
required THA. The predictive validity of outcome measures
is an important consideration in choosing study end-
points and is of particular clinical relevance in the study of
chronic disease. This cut-off point requires validation in
similar studies conducted in other countries with different
healthcare systems.
Composite indices
OMERACT-OARSI RESPONDER CRITERIA: COMPOSITE INDEX OF
SYMPTOMATIC VARIABLES
Initiatives by members of the international rheumatology
community have yielded a uniform set of outcome
measures for OA2,12–14. Using data from previously con-
ducted placebo-controlled clinical trials, the Osteoarthritis
Research Society International (OARSI) Standing Com-
mittee for Clinical Trials conducted statistical analyses to
identify the response criteria that best discriminated active
agents from placebo. On the basis of these analyses, the
committee proposed two sets of response criteria for clini-
cal trials based on three symptomatic domains, i.e., pain,
function and the patient’s global assessment15. For each
domain, response was defined by both a relative and
absolute change and different cutoffs were specified for
different drugs, routes of administration, and OA sites.
Recently, this committee further evaluated the perform-
ances of these two sets of response criteria as well
as modifications of these proposed by the scientific
OMERACT committee16. The objective of these evalua-
tions was to identify a simplified set of responder criteria
with similar cut-off values across different OA drugs, routes
of administration, and OA sites. On the basis of data-driven
Fig. 2. Kaplan-Meier estimates of the cumulative probabilities of
not having total hip arthroplasty according to the decrease in joint
space width below or above the cut-off point of -0.4 mm. (Reprinted
from Maillefert JF, Gueguen A, Nguyen M, Berdah L, Lequesne M,
Mazieres B, Vignon E, Dougados M. Relevant change in radiologi-
cal progression in patients with hip osteoarthritis. I. Determination
using predictive validity for total hip arthroplasty. Rheumatology
[Oxford] 2002;41[2]:145 by permission of the British Society for
Rheumatology.)
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analyses and expert opinion, the committee recommended
the optimal simplified set of responder criteria for OA
clinical trials shown in Fig. 317. This OMERACT-OARSI set
of criteria provides a simplified definition of symptomatic
improvement, allowing assessment of individual patient
response on the basis of both pain and function. Additional
study is needed to validate this proposed set of criteria.
TOTAL HIP REPLACEMENT CRITERION: COMPOSITE INDEX OF
VARIABLES FROM SYMPTOMATIC AND STRUCTURAL DOMAINS
Because treatments that favorably influence clinical
symptoms may at the same time have a deleterious effect
on structural elements, international scientific committees
have suggested that both symptomatic and structural vari-
ables of OA should be assessed in clinical studies2,12,14. It
would be useful to have a composite index that would
combine this information into a single variable. The require-
ment for THA has been proposed as a composite outcome
measure for trials of hip OA based on the assumption that
THA is performed only in patients who have severe disease
from both a symptomatic and structural standpoint18. This
variable, which has been included in the guidelines or
recommendations of both American and European regulat-
ory agencies, fulfils several of the characteristics required
of outcome variables for OA, including simplicity, reproduc-
ibility, sensitivity to change, discriminant capacity, and face
validity. The degree to which these characteristics apply to
THA in OA were evaluated in the ECHODIAH study10,18.
The study asked the question: Does the requirement for
surgery reflect the severity of OA?
The validity of THA as an outcome measure was evalu-
ated by comparing symptomatic and structural variables
between the group of patients who required THA and those
who did not. The results of this comparison showed signifi-
cant differences between the two groups (Table II). These
differences suggested that the patients who required THA
had significantly more severe and progressive disease than
the patients who did not require THA, suggesting in turn
that THA can be considered a valid measure of the severity
of OA.
The sensitivity of this parameter to change was evalu-
ated by determining the percentage of patients who
required THA during the 3-year study using a life table
analysis technique (Kaplan–Meier). Over the course of the
3-year study, 106 of the 506 patients were referred to
surgery. The percentage of patients who required surgery
was 8% per year (Fig. 4) and was consistent over the
course of the 3-year study. We have continued to follow
this cohort for 8 years. Follow-up data at 5 years indicate
that the 8% annual rate of THA has remained constant
throughout this period (unpublished data).
The discriminant capacity of THA, or the ability of this
outcome measure to discriminate between a chondro-
modulating treatment and a placebo, was also evaluated in
the ECHODIAH study10. Discriminant capacity is an import-
ant consideration, although at present there is no gold
Fig. 3. OMERACT-OARSI set of responder criteria. (Reprinted with permission from Pham et al.17.)
Table II
Symptomatic and structural variables in the 506 patients with hip
OA with regard to the necessity for hip surgery during the 3 years
of the study (Reprinted from Reference 18 with permission from the
Journal of Rheumatology.)
THA during the study*
Characteristic Yes
(N=106)
No
(N=400)
Symptomatic variables
Pain, VAS
Last value 71±24 36±27
Mean change during the study +5±22 −9±21
Lequesne index
Last value 13±4 6±4
Mean change during the study +1±3 −2±2
Structural variable
Radiological joint space width, mm
Last value, mm 0.8±0.9 1.8±1.0
Mean change during study, mm/year −1±1.4 −0.2±0.50
Change >0.5 mm 67% 35%
OA=osteoarthritis; THA=total hip arthroplasty; VAS=visual ana-
log scales.
*For each characteristic, intergroup comparison showed a highly
statistically significant difference (P<0.0001) (Student’s t test or chi
squared test.) OA=osteoarthritis; THA=total hip arthroplasty;
VAS=visual analog scales.
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standard for comparison since there is currently no univer-
sally effective treatment for OA. The objective of the study
was to evaluate the ability of the interleukin-1 beta inhibitor
diacerein to slow the progressive decrease in JSW in
patients with hip OA. The percentage of patients who
underwent THA was determined as a secondary variable.
To explore the ability of the requirement for THA to differ-
entiate between study treatments, the investigators com-
pared the percentage of patients undergoing THA by
treatment groups (diacerein versus placebo). Hip replace-
ment surgery was performed in 19.8% in the placebo
group, compared with 14.5% in the diacerein group
(P=0.286). Although this difference did not reach statistical
significance, the comparison of the survival curves of the
two groups showed a trend in favor of the diacerein
treatment group.
These data suggest that requirement for THA is a valid,
simple, clinically pertinent outcome parameter that can be
considered a useful composite index. Nevertheless, this
end-point has been criticized because of the wide inter-
national variability in the frequency of THAs, most likely a
result of differences in health care systems. Also, the
decision to perform THA is influenced not only by par-
ameters related to OA severity, but also by concomitant
disease and the patient’s willingness to undergo surgery.
This criticism has led to the suggestion that the time to fulfil
the criteria for considering THA should replace time to
surgery as the appropriate end-point19.
In a recent publication based on data from the cohort of
patients from the ECHODIAH study18, Maillefert et al.
proposed a composite index for THA in patients with hip
OA19. The index was selected on the basis of the best
combination of variables to predict the occurrence of
THA. The authors conducted a multivariate logistic
regression in which the dependent variable was the
occurrence of THA and the independent variables were
radiologic and symptomatic variables (Table III). The time-
dependent covariates used in the model included radio-
logical JSW, patient’s global assessment, Lequesne
index, pain, and NSAID and analgesic intake. For each
covariate, an estimated parameter (EP), the relative risk
for occurrence of THA, was determined. From each EP, a
coefficient (EP×100/maximal potential value of the sum of
EP) was calculated. The score was defined as the sum of
all coefficients. Higher scores were indicative of a greater
risk of THA. Graphic representation of the correct classifi-
cation probabilities indicated that the best cut off value for
prediction of THA was 40. The authors noted that this
composite index should be regarded as preliminary and
validated in further studies.
Conclusions
Monitoring the progression of osteoarthritis (OA) and the
effects of therapy during clinical trials requires the use of
valid and reliable outcome measurements that are simple
to perform and sufficiently sensitive to detect changes in
the patient’s condition. Four domains--pain, physical func-
tion, patient global assessment, and joint imaging (for
studies 1 year in duration) – have been identified as core
outcome measures that should be evaluated in Phase III
clinical trials of knee, hip, and hand OA. Although analysis
of these variables is often based on the average improve-
ment for the study population as a whole, expression of
Fig. 4. Percentage of patients who required total hip arthroplasty
(THA) over the 3 years of the study. (Reprinted from Reference 18
with permission from the Journal of Rheumatology.)
Table III
Results of multivariate logistic regression in which the occurrence of total hip arthroplasty (THA) was the dependent variable and the
independent variables were symptomatic and therapeutic variables collected at a single visit together with the radiological variables
(Reprinted from Reference 19 with permission from the Journal of Rheumatology.)
Time Dependent Covariates Grades of the
Covariates
Relative
Risk*
95% CI Rounded Off
Coefficient†
Joint space width on the last available radiograph (mm) >2 1 0
≤2 and >1 3.9 1.8–9.16 20
≤1 11.68 5.78–26.28 35
Patient’s overall assessment (0-4 scale: none to very severe; value collated
at the evaluated visit)
<2 1 0
>2 2.85 1.53–5.32 15
Lequesne index (0-24 scale; value collated at the evaluated visit) ≤12 1 0
>12 5.62 3.13–10.15 25
NSAID intake during the 3 mo preceding the evaluated visit ≤1 day/2 1 0
>1 day/2 2.31 1.34–3.94 15
Analgesic intake during the 3 mo preceding the evaluate visit ≤1 day/week 1 0 0
>1 day/week 1.98 1.16–3.4 10
CI=confidence interval; THA=total hip arthroplasty; EP=estimated parameter.
*Relative risk for occurrence of THA during the 3 months following the evaluated visit.
†Coefficient=EP×100/maximal potential value of the sum of EP, in which EP=Ln of relative risk for the occurrence of THA during the 3
months following the evaluated visit. Coefficients were rounded to obtain an easy-to-use instrument.
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results in terms of individual patients is more relevant. It is
desirable, therefore, to present results as a dichotomous
response variable, such as improvement or no improve-
ment, so that the percentage of patients responding to
treatment can be determined. Continuous data from indi-
vidual patients data may be converted to a dichotomous
variable based on global assessments, statistical modeling,
or predictive capacities. Such methods suggest that
changes in JSW of >0.4 mm may be considered clinically
significant. Because both symptomatic and structural vari-
ables of OA should be assessed in clinical studies, an
important next step in advancing the design of trials of
treatments for OA is to combine these variables into a
single composite index. The requirement for THA has been
proposed as such a composite variable and shown to be a
valid, simple, clinically pertinent outcome parameter that
may be a useful composite index in studies of OA.
References
1. OMERACT Initiative web site. Available at: http://reuma.
rediris.es/omeract/whatis.html. Accessed November
21, 2002.
2. Bellamy N, Kirwan J, Boers M, Brooks P, Strand V,
Tugwell P, et al. Recommendations for a core set of
outcome measures for future Phase III clinical trials
in knee, hip, and hand osteoarthritis. Consensus
development at OMERACT III. J Rheumatol 1997;24:
799–802.
3. Bellamy N, Buchanan WW, Goldsmith CH, Campbell
J, Stitt LW. Validation study of WOMAC: a health
status instrument for measuring clinically important
patient relevant outcomes to antirheumatic drug
therapy in patients with osteoarthritis of the hip or
knee. J Rheumatol 1988;15:1833–40.
4. Lequesne MG, Mery C, Samson M, Gerard P. Indexes
of severity for osteoarthritis of the hip and knee.
Validation--value in comparison with other assess-
ment tests. Scand J Rheumatol Suppl 1987;65:85–9.
5. Meenan RF, Mason JH, Anderson JJ, Guccione AA,
Kazis LE. AIMS2. The content and properties of a
revised and expanded Arthritis Impact Measurement
Scales Health Status Questionnaire. Arthritis Rheum
1992;35:1–10.
6. Ehrich E, Davies G, Watson D, Bolognese J,
Seidenberg B, Bellamy N. Minimal perceptible clinical
improvement (MPCI) in osteoarthritis: WOMAC and
global assessments, influence of age, gender and
geographic region (Abstract #438). Arthritis Rheum
1999;42(Suppl):S143.
7. Maillefert JF, Nguyen M, Gueguen A, Berdah L,
Lequesne M, Mazieres B, et al. Relevant change in
radiological progression in patients with hip osteo-
arthritis. II. Determination using an expert opinion
approach. Rheumatology (Oxford) 2002;41:148–52.
8. Dougados M, Gueguen A, Nguyen M, Berdah L,
Lequesne M, Mazieres B, et al. Radiological progres-
sion of hip osteoarthritis: definition, risk factors and
correlations with clinical status. Ann Rheum Dis
1996;55:356–62.
9. Bland JM, Altman DG. Statistical methods for assess-
ing agreement between two methods of clinical
measurement. Lancet 1986;1:307–10.
10. Dougados M, Nguyen M, Berdah L, Mazieres B,
Vignon E, Lequesne M. for the ECHODIAH Investi-
gators Study Group. Evaluation of the structure-
modifying effects of diacerein in hip osteoarthritis:
ECHODIAH, a three-year, placebo-controlled trial.
Evaluation of the Chondromodulating Effect of
Diacerein in OA of the Hip. Arthritis Rheum 2001;
44:2539–47.
11. Maillefert JF, Gueguen A, Nguyen M, Berdah L,
Lequesne M, Mazieres B, et al. Relevant change in
radiological progression in patients with hip osteo-
arthritis. I. Determination using predictive validity for
total hip arthroplasty. Rheumatology (Oxford) 2002;
41:142–7.
12. Altman R, Brandt K, Hochberg M, Moskowitz R,
Bellamy N, Bloch DA, et al. Design and conduct of
clinical trials in patients with osteoarthritis: recom-
mendations from a task force of the Osteo-
arthritis Research Society. Results from a workshop.
Osteoarthritis Cartilage 1996;4:217–43.
13. Lequesne M, Brandt K, Bellamy N, Moskowitz R,
Menkes CJ, Pelletier JP, et al. Guidelines for testing
slow acting drugs in osteoarthritis. J Rheumatol
Suppl 1994;Sep 41:65–71 discussion 72-3.
14. Group for the Respect of Ethics and Excellence in
Science (GREES). Recommendations for the regis-
tration of drugs used in the treatment of osteoarthritis.
Group for the respect of ethics and excellence in
science (GREES): osteoarthritis section. Ann Rheum
Dis 1996;55:552–7.
15. Dougados M, Leclaire P, van der Heijde D, Bloch DA,
Bellamy N, Altman RD. Response criteria for clinical
trials on osteoarthritis of the knee and hip: a report of
the Osteoarthritis Research Society International
Standing Committee for Clinical Trials response
criteria initiative. Osteoarthritis Cartilage 2000;8:
395–403.
16. Pham T, van der Heijde D, Altman R, Anderson J,
Bellamy N, Hochberg M, et al. OMERACT-OARSI
Initiative: OARSI set of responder criteria for osteo-
arthritis (OA) clinical trials revisited (Abstract). Pre-
sented at the World Congress on Osteoarthritis;
22–25 September, 2002; Darling Harbor, Sydney,
Australia.
17. Pham T, Van Der Heijde D, Lassere M, Altman RD,
Anderson JJ, Bellamy N, et al. Outcome Variables for
Osteoarthritis Clinical Trials: The OMERACT-OARSI
Set of Responder Criteria. J Rheumatol. 2003;30:
1648–54.
18. Dougados M, Gueguen A, Nguyen M, Berdah L,
Lequesne M, Mazieres B, et al. Requirement for total
hip arthroplasty: an outcome measure of hip
osteoarthritis? J Rheumatol 1999;26:855–61.
19. Maillefert JF, Gueguen A, Nguyen M, Berdah L,
Lequesne M, Mazieres B, et al. A composite index
for total hip arthroplasty in patients with hip
osteoarthritis. J Rheumatol 2002;29:347–52.
S60 M. Dougados: Monitoring osteoarthritis progression
